Amivantamab Plus Lazertinib Improves PFS Irrespective of ...
Amivantamab-vmjw plus lazertinib significantly improved progression-free survival (PFS) over osimertinib in high-risk EGFR-mutant NSCLC patients, showing a 30% reduced risk of disease progression or death and a 7.1-month PFS improvement. Superior outcomes were noted in patients with TP53 co-mutations, detectable ctDNA, brain, and liver metastases.
Related Clinical Trials
Reference News
Amivantamab plus lazertinib significantly improves progression-free survival (PFS) over osimertinib in high-risk EGFR-mutant NSCLC patients, with a 30% risk reduction in disease progression or death. Superior outcomes were noted across various high-risk features, including brain and liver metastases, TP53 co-mutations, and ctDNA clearance, establishing it as a promising first-line treatment.
Amivantamab-vmjw plus lazertinib significantly improved progression-free survival (PFS) over osimertinib in high-risk EGFR-mutant NSCLC patients, showing a 30% reduced risk of disease progression or death and a 7.1-month PFS improvement. Superior outcomes were noted in patients with TP53 co-mutations, detectable ctDNA, brain, and liver metastases.